V10XX02 • ibritumomab tiuxetan • Various | Other therapeutic radiopharmaceuticals | Various therapeutic radiopharmaceuticals
Ibritumomab tiuxetan is a radioactive monoclonal antibody used for the treatment of non-Hodgkin's lymphoma. It works by binding to the CD20 antigen on the surface of B-lymphocytes, destroying cancer cells through radiation and immune mechanisms.
The medication is administered intravenously, as directed by a doctor, and requires careful monitoring for adverse effects.
Side effects may include nausea, fever, fatigue, decreased blood cell counts, or allergic reactions. In rare cases, severe infections or tumor lysis syndrome may occur.
Ibritumomab tiuxetan is not recommended for patients with hypersensitivity to this medication or active severe infections.
Substance: ibritumomab tiuxetan
Date of last drug list: 01-07-2013
Commercial code: W42167001
Concentration: 1.6mg / ml
Pharmaceutical form: kit
Quantity: 1
Product type: original
Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.